LivaNova PLC (LIVN)

Market Cap	2.17B
Revenue (ttm)	1.25B
Net Income (ttm)	63.23M
Shares Out	54.35M
EPS (ttm)	1.16
PE Ratio	34.41
Forward PE	11.01
Dividend	n/a
Ex-Dividend Date	n/a

Volume	458,329
Open	40.47
Previous Close	40.37
Day's Range	39.59 - 40.76
52-Week Range	36.85 - 64.48
Beta	1.11
Analysts	Buy
Price Target	60.29 (+51.03%)
Earnings Date	Apr 30, 2025

About LIVN

LivaNova PLC, a medical technology company, designs, develops, manufactures, markets, and sells products and therapies for neurological and cardiac conditions worldwide. The company operates in two segments, Cardiopulmonary and Neuromodulation. The Cardiopulmonary segment provides cardiopulmonary products, including heart-lung machines, oxygenators, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related accessories. The Neuromodulation segment offers VNS Therapy System, an implantable pulse generator and connect...

• Industry: Medical Devices
• Sector: Healthcare
• IPO Date: Feb 10, 1993
• Employees: 2,900
• Stock Exchange: NASDAQ
• Ticker Symbol: LIVN
• Website: https://www.livanova.com

Financial Performance

In 2024, LivaNova's revenue was $1.25 billion, an increase of 8.66% compared to the previous year's $1.15 billion. Earnings were $63.23 million, an increase of 260.39%.

Analyst Forecast

According to 7 analysts, the average rating for LIVN stock is "Buy." The 12-month stock price forecast is $60.29, which is an increase of 51.03% from the latest price.

Price Target

$60.29

(51.03% upside)

Analyst Consensus: Buy